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ARTICLE
A two-stage inter-rater approach for enrichment testing
of variants associated with multiple traits
Jennifer L Asimit*,1,2, Felicity Payne1, Andrew P Morris3, Heather J Cordell4,5 and Inês Barroso1,5
Shared genetic aetiology may explain the co-occurrence of diseases in individuals more often than expected by chance.
On identifying associated variants shared between two traits, one objective is to determine whether such overlap may be
explained by specific genomic characteristics (eg, functional annotation). In clinical studies, inter-rater agreement approaches
assess concordance among expert opinions on the presence/absence of a complex disease for each subject. We adapt a
two-stage inter-rater agreement model to the genetic association setting to identify features predictive of overlap variants, while
accounting for their marginal trait associations. The resulting corrected overlap and marginal enrichment test (COMET) also
assesses enrichment at the individual trait level. Multiple categories may be tested simultaneously and the method is
computationally efficient, not requiring permutations to assess significance. In an extensive simulation study, COMET identifies
features predictive of enrichment with high power and has well-calibrated type I error. In contrast, testing for overlap with a
single-trait enrichment test has inflated type I error. COMET is applied to three glycaemic traits using a set of functional
annotation categories as predictors, followed by further analyses that focus on tissue-specific regulatory variants. The results
support previous findings that regulatory variants in pancreatic islets are enriched for fasting glucose-associated variants, and
give insight into differences/similarities between characteristics of variants associated with glycaemic traits. Also, despite
regulatory variants in pancreatic islets being enriched for variants that are marginally associated with fasting glucose and fasting
insulin, there is no enrichment of shared variants between the traits.
European Journal of Human Genetics (2017) 25, 341–349; doi:10.1038/ejhg.2016.171; published online 21 December 2016
INTRODUCTION
Apparent links between disease susceptibilities may be explained by
shared genetic aetiology, such that a variant may be associated with
multiple traits. Besides identifying shared associated variants, a further
objective is to determine whether the overlap of associated variants
between the traits may be related to SNP (or trait × SNP)-specific
characteristics. Identification of specific characteristics that are pre-
dictive of overlap enables refinement of the set of variants in further
searches for predisposing variants of both traits. Moreover, Bayesian
priors may be defined such that a SNP belonging to a predictive
category has a higher prior probability of association than SNPs
outside that category; priors may also be allowed to differ so that the
prior probability increases with the number of predictive categories
that the SNP belongs to. The overall purpose of the proposed method,
corrected overlap and marginal enrichment test (COMET), is to
determine whether agreement (overlap) between the verdicts of
association between a SNP and a phenotype can be related to SNP-
specific (eg, functional annotation) or trait × SNP-specific character-
istics, such as membership of known biological pathways.
Several existing methods address similar, but distinctive, objectives;
for example, GoShifter,1 genetic analysis incorporating pleiotropy and
annotation (GPA),2 and a method implemented in database for
annotation, visualisation and integrated discovery (DAVID).3 All of
these methods assess enrichment of annotations among trait-
associated variants and, on application to shared variants between
different traits, do not account for marginal enrichment of individual
traits. Testing for annotation enrichment within trait-associated SNPs
is the reverse of the proposed objective of testing for enrichment of
trait-associated variants within annotations. In the latter, the number
of associated variants is treated as the random variable, which aligns
with the perception that we observe a number of associated variants
and there are more to discover. In contrast, testing for annotation
enrichment in a set of associated SNPs fixes the number of
associations found and assesses annotation status among them; the
annotation status is treated as the random variable in that approach.
With regards to overlap enrichment extensions, any of the single-
trait enrichment methods may be extended by considering the set of
SNPs associated with two traits. However, this does not automatically
account for enrichment due to chance, as the marginal distributions of
the individual traits are not accounted for. The GPA approach uses
annotation information to increase the statistical power to identify risk
variants. The authors of the method recommend caution in inter-
preting the enrichment testing approach of GPA with respect to
overlap variants, as a significant P-value may be due to marginal
enrichments.2 GoShifter uses a computationally intensive permutation
approach1 and the test implemented in DAVID involves calculation of
a hypergeometric probability.3 We apply DAVID to test for enrich-
ment among shared variants, rather than variants associated with a
single trait and demonstrate that it has an increased type I error rate.
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Owing to the inflated error, power comparisons are not carried out
with DAVID.
COMET requires only summary statistics and is applicable to case–
control or quantitative trait studies that may or may not have
overlapping individuals. Simulations demonstrate that any degree of
overlap between studies does not inflate the type I error for detection
of SNP characteristics that are predictive of concordant associations
between the traits. As COMET only requires fitting several linear
models and does not depend on permutations to assess significance, it
is computationally efficient. The data only needs to be clumped once,
and then may be quickly analysed with any set of covariates. On a
Linux (64 bit) machine with X86-64 architecture, 32 cores, and
2× 2.1 Ghz 12 core AMD 6272 CPU, on data that has already been
clumped, COMET is able to run for one pair of traits and one set of
five covariates in 3 min, 44 s for our data application, where the fitting
of the models takes 36 s.
There is flexibility in the covariates that may be incorporated in the
analysis, leading to a range of potential applications. Before our real
data application, we first examine the potential for a set of functional
annotation covariates to differentiate between associated variants
(with Po5× 10− 6, as given by the National Human Genome Research
Institute (NHGRI) Genome-Wide Association Study (GWAS)
catalogue4) for 14 different diseases/traits. COMET is then employed
with these covariates to assess whether any annotation class is enriched
for variants associated with fasting insulin, fasting glucose or 2-h
glucose, or enriched for shared associations between any pair of the
three glycaemic traits (from the Meta-Analyses of Glucose and Insulin-
related traits Consortium; MAGIC). As more genome-wide significant
loci have been identified for the glucose traits than for fasting insulin,5
an objective is to determine whether there are certain characteristics
that are enriched for variants associated with either or both traits; such
features may then be used for refinement of searches for further
associated variants. On the basis of our results, we proceed with
further analyses using COMET to test for enrichment of trait(s)-
associated variants within tissue-specific regulatory regions. The soft-
ware for COMET is freely available at http://www.sanger.ac.uk/
science/tools/comet.
MATERIALS AND METHODS
Studies of agreement are common in clinical studies and psychiatric research,
where one is often interested in the agreement among expert/rater opinions.
A special case is when the opinion/rating is a dichotomous outcome, such as a
diagnosis. Inter-rater agreement approaches give a measure of the concordance
between two raters (eg, physicians) that make a verdict or pronouncement
(eg, disease presence/absence) on the same subject, and adjust for agreement
between raters that may occur simply due to chance. A two-stage inter-rater
agreement model identifies covariate categories containing more concordance/
discordance in verdicts than expected by chance, accounting for the marginal
rater opinions.6 We adapt this model to the genetic association setting to
identify features predictive of shared associations at a SNP, accounting for the
marginal trait associations; each ‘subject’ corresponds to a SNP, whereas each
‘rater’ corresponds to a trait. It may also be used to assess features predictive of
association for individual traits.
At each genetic variant, a binary variable is defined for each trait
corresponding to evidence of association with the trait, based on a pre-
specified significance threshold; this corresponds to the verdict of each rater.
Analogous to comparing measurements taken by raters on the same indivi-
duals, we compare measurements of trait-association at each SNP. Rather than
considering agreement for both traits (ie, either having or not having
association evidence at the same SNP), we focus only on both traits having
association evidence, as lack of association evidence does not imply that the
association does not exist (eg, due to lack of power).
Evidence of association for each trait with each SNP may be defined
according to P-values or Bayes’ factors (BFs). We focus on BFs, as BFs may be
easily computed from summary statistics7 and have several advantages over
P-values in the comparison of multiple studies.8 In both our simulations and
data application, we used a Bayesian threshold of log10(ABF)40.695 (based on
threshold settings R= 20, π0= 0.99), corresponding to a P-value threshold of
0.004–0.01, depending on the study size;8 see Supplementary Information for
BF details.
Model
We consider SNP-specific and/or trait × SNP-specific covariates based on prior
genetic information such as biological annotations. Covariate categories may
then be tested for enrichment of (marginal and/or shared) associated variants.
As the inter-rater methods assume independent subjects (with subjects here
corresponding to SNPs), we first prune (r240.1) the set of SNPs (minor allele
frequency (MAF)45%) that comprise the GWAS data for each trait. The MAF
threshold of 5% was chosen as we focus on GWAS results, though in
application to other data sets (eg, large samples of exome data) lower MAF
variants may be included. SNPs are clumped using r240.1 to satisfy the
independence assumption required for the regression models. We make use of
a joint association metric that accounts for the significance of a SNP with
respect to each trait, maximising the retention of SNPs associated with multiple
traits, rather than SNPs with high association evidence with one trait and not
with the other8 (see Supplementary Information for details).
Let xi be a vector of SNP-specific covariates, xir be a vector of SNP-trait-
specific covariates, Yir= 1 (evidence of association at SNP i for trait r); r= 1, 2,
and pir=Pr(Yir= 1|xi, xir); r= 1, 2; i= 1,...,m. In the inter-rater model,6
agreement between the raters at subject i would be defined as Yi=Yi1Yi2
+(1−Yi1) (1−Yi2). Instead, we focus on the concordance of associated SNPs,
and therefore consider Yi=Yi1Yi2. The marginal models for conditional
probability of a detected association given a particular trait (r= 1, 2) are:
logitðpirÞ ¼ g0r þ xir 0g1r þ xi 0g2r:
The intercept term γ0r is the baseline probability of association, accounting for
the probability of association that is not attributable to any of the covariates. An
effect estimate that meets the significance threshold (eg, 0.05) and is positive
suggests that SNPs within the coinciding covariate category tend to be
associated with the trait (ie, positive enrichment); negative enrichment is
present if the significant effect estimate is below zero. Collectively, this model
tests for covariate categories that are predictive of SNP-trait associations.
These marginal models are first fit independently for each trait, then the
fitted models are used to obtain estimates of the log-odds of chance overlap
term Z^ ¼ logit p^ i1p^ i2ð Þ, which accounts for chance overlap, assuming that the
probabilities of association at each trait are independent (if modelling
agreement rather than concordance of association one would instead have
Z^ ¼ logit p^ i1p^ i2 þ 1 p^ i1ð Þ 1 p^ i2ð Þ½ ). This term is then used as an offset term
in the model for the probability of overlapping associations (or agreement):
logitðpiÞ ¼ Z^ i þ b0 þ xi1 0b1 þ xi2 0b2 þ xi 0b:
If overlap is due to chance alone, then all covariate effect estimates are not
significantly different from zero and the probability of overlap is simply the
product of the marginal probabilities, logit1 Z^ ið Þ. This observation helps us
make inferences on the features of SNPs for which there is an enrichment of
overlapping associations. A statistically significant intercept term β0 would be
suggestive of more agreement than expected by chance that is not accounted for
by any of the covariates. For instance, if SNPs associated with one trait tend to
be associated with the other trait, but this sharing of associations is not related
to any of the covariates, then the intercept term would account for this
agreement. This framework may easily be extended to identify predictive
features of shared SNPs for R traits by defining agreement at SNP i as
Y i ¼
QR
r¼1 Y ir. In our particular application to three glycaemic traits, there
were only six SNPs that were shared between all three traits. Therefore, little
inference could be made on the features of this small set of SNPs, and we
proceeded by applying COMET to each pair of traits.
The traits may be from studies composed of disjoint sets of individuals or
possibly from studies that share some individuals in common. In particular, for
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two quantitative traits, measurements for both traits may be taken on a portion
of individuals. In the usual inter-rater set-up, different raters have correlated
responses by the nature of rating the same subject, which is akin to correlation
between trait associations expected in the presence of shared individuals, when
testing at a certain SNP. This may influence the overall probability of
concordance between the ratings but, intuitively, although this will affect the
intercept term, this should not affect the tests of whether or not any of the
covariates explain the concordance in the ratings. In the scenario of two case–
control studies, there is the possibility of shared individuals between the control
sets of the two studies. These shared controls may influence the individual SNP
association tests, but by similar reasoning to the quantitative traits case, only the
intercept term is expected to experience an impact. On a similar note, the traits
may be correlated (eg, height and birth weight) or linked through a phenotypic
derivation (eg, height and kg/m2), as the offset term accounts for each of the
marginal distributions when testing for enrichment among shared variants.
Full marginal models for pir are recommended, such that any covariates that
are considered for inclusion in the overlap model are included in each marginal
model. This prevents spurious results in the overlap model for pi, as p^ir are
needed to estimate the offset term.6 In the final overlap model, covariates of
categories containing no overlap SNPS are removed.
It has been noted that the variance estimates for each coefficient of the model
for pi assume that the offset term is known rather than estimated, so that
alternative approximation techniques such as the jackknife are suggested.6
A jackknife estimate of the variance may be obtained by a leave-one-out
procedure in which each subject (SNP) is removed and the two-stage models
are fit to the data with one fewer subjects. However, as there are a large number
of SNPs, there are negligible changes to the fitted models at the removal of each
individual SNP. Therefore, for computational efficiency, we make use of the
resulting coefficient estimates and standard errors from the model based on a
known offset term. A flow chart for COMET is given in Figure 1.
Covariates
Various SNP-specific covariates may be used to inform about overlap between
traits, allowing flexibility in use of the method. A set of possible SNP-specific
covariates is listed in Table 1, which is a modification of categories that have
previously been considered when making use of prior knowledge for prioritis-
ing SNPs for follow-up.9 Covariate categories that each SNP is positive for are
determined by the Variant Effect Predictor (VEP, v81) of Ensembl,10 which
outputs all consequences of each variant on the protein sequence and gene
expression, across all transcripts for the gene, so that a SNP may be positive for
multiple covariate categories.
Figure 1 Flow chart of inter-rater approach to overlap analysis of two traits. Ta
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As a reference to the general features of SNPs, we examine the distribution of
SNPs from the 1000 Genomes CEU samples, phase 3 release.11 On pruning the
common SNPs (MAF40.05) on r240.1 (using PLINK v1.07), there are
208 780 approximately independent variants. Table 1 provides the proportion
of these SNPs that belong to each of the covariate categories, as well as the
coinciding proportions for unpruned common SNPs. These proportions show
a close correspondence, suggesting that the pruned SNPs reflect the overall
distribution seen in the common SNPs in CEU of 1000 Genomes.
Simulations
Each simulation is based on 208 780 approximately independent SNPs that
remain after pruning the common SNPs on r240.1 in the 1000 Genomes CEU
samples. Functional annotations for these SNP are obtained from VEP (v79).
We focus on models that include five SNP-specific covariates that are listed in
Table 1, namely Q1, Q2, Q3, Q5 and Q6 that are positive in 51.5%, 0.39%,
0.54%, 1.40%, and 64.1% of SNPs, respectively; Q4 is not included in the
models as o0.025% of the pruned SNPs fall within this category. Several
technical details regarding differences between these simulation proportions
and those of Table 1 are detailed in the Supplementary Information.
For assessment of power, only one of the five covariate categories (Q1 or Q5)
is set as enriched for overlapping associations between the traits, though this
does not restrict causal SNPs from belonging to other categories. We consider
various proportions p12’ of variants that are associated with both traits and
belong to the enriched category. The overall proportion of overlap variants is
denoted by p12, whereas the marginal proportions of SNPs associated with traits
1 and 2 are given by p1 and p2, respectively. The simulation algorithm,
parameter selection, and technical details are given in the Supplementary
Information. For each parameter setting, we run 1000 replications to
approximate type I errors and power. Type I errors are approximated from
simulations that do not assign enrichment to any of the covariate categories,
such that overlapping variants are present and there is no restriction on their
allocation to covariate categories; this mimics the natural distribution of SNPs
among the covariate categories. For further assessment of any inflation, we also
consider QQ-plots of the standardised effect estimates compared with a
standard normal distribution, as well as inflation factors (calculated from the
median of χ2 distribution). As a comparison, type I errors for enrichment
testing of overlap variants are also determined via the DAVID software.3
Real data application
Before applying COMET to real data, we considered the distribution of the
covariates among variants that are associated with fourteen traits/diseases. This
pre-assessment illustrated that there is potential for the covariates to differ-
entiate between trait-associated variants for different traits, as well as potential
for identifying covariates that may be enriched for shared variants. Details and
results on these comparisons are given in the Supplementary Information and
in Supplementary Figure S5.
COMET was applied with the set of five functional annotation covariates to
each pair of fasting insulin, fasting glucose and 2-h glucose, which were all
measured on non-diabetic European-ancestry individuals (from MAGIC). The
summary statistics from these glycaemic traits were downloaded from www.
magicinvestigators.org and details on this dataset are provided in the
Supplementary Information. Rather than restricting certain covariates to tests
of positive enrichment (due to small covariate proportions) and others to two-
sided tests (of positive or negative enrichment) in the overlap model, we
simplify the presentation and focus only on positive enrichment. We further
demonstrate how COMET could be used to explore regulatory annotation in
greater depth by making use of an extensive database on regulatory informa-
tion, RegulomeDB, which covers over 100 tissue and cell lines.12 In
RegulomeDB, known and predicted regulatory DNA elements include regions
of DNase hypersensitivity, binding sites of transcription factors, and promoter
regions that have been characterised to regulation transcription.
Of particular interest are tissues that are involved in metabolism, i.e.
pancreas, liver, cardiac muscle, skeletal muscle, and adipose tissues. Pancreatic
islet cells are central in the pathogenesis of type 2 diabetes (T2D) and active islet
enhancer clusters have been demonstrated to be enriched in T2D risk-
associated and fasting glucose-associated variants.13 In addition, liver, adipose
tissue, and skeletal and cardiac muscles develop insulin resistance as defence
against damage from an excess nutrient load.14
Owing to the likely collinearity between the tissue-specific regulatory
covariates, we ran separate models including one regulatory covariate annotated
by RegulomeDB, for several filtrations on the tissue type(s); details of the
specific cell/tissue lines within each tissue group are provided in the
Supplementary Information. Initially, eight models were considered: one for
each of the five metabolism-involved tissues, liver cancer (as a tissue that is
involved in metabolism, but cancerous so may/may not be enriched for
glycaemic trait-associated variants), the union of the five metabolism-involved
tissues, and the collection of all tissues available in RegulomeDB. As the
pancreatic tissue group consists of tissues from both pancreatic islets and the
pancreatic duct, we also compared our results when only pancreatic islets are
included. The respective proportions of pruned variants (r2o0.1) that are
regulatory in each tissue type are 0.0768 (pancreas), 0.0666 (pancreatic islets
only), 0.0779 (liver), 0.0275 (cardiac muscle), 0.116 (skeletal muscle), 0.0012
(adipose), and 0.0955 (liver cancer). On considering all (5) tissues involved in
metabolism, the proportion is 0.166, or 0.162 if pancreatic duct tissues are
excluded. Among all available tissues, the proportion of regulatory variants
is 0.693.
RESULTS
Simulation study
Two equal-sized case–control studies were generated, where study
r (for trait r; r= 1, 2) is composed of Nr cases and Nr controls; we
consider study 1 with N1= 3000 each of cases and controls and study 2
with N2= 5000 each of cases and controls, as well as (N1, N2) taking
values (5000, 10 000) and (10 000, 20 000). In our null simulations,
the proportions of trait-associated variants for trait 1 (marginal), trait
2 (marginal) and shared between them are, respectively, p1= 0.04,
p2= 0.02 and p12= 5× 10− 4. For all five covariates, both sets of
standardised effect estimates from the marginal models display a close
alignment with the standard normal distribution (eg, see
Supplementary Figure S1). The coinciding inflation factors for
covariates Q1, Q2, Q3, Q5, and Q6 are, respectively, 1.07, 1.19,
1.09, 0.97, and 1.08, which are not substantially over-inflated, though
the smallest category Q2 (containing o0.5% of the variants), appears
to be most inflated.
For detecting positive enrichment of overlap variants at significance
level α= 0.05, type I error estimates for COMET and DAVID are given
in Table 2. The type I errors of DAVID are consistently higher than
those based on COMET, and the 95% confidence intervals for the
three categories with fewer than 2% of the variants (Q2, Q3, Q5) are
well above 0.05. COMET has a better controlled type I error rate, as
the 95% confidence intervals contain 0.05 or have an upper bound
that is slightly below it.
Positive-enrichment overlap tests with COMET are well-calibrated
for all covariates, though tests for negative enrichment are less well-
calibrated for covariates Q2, Q3, and Q5 (eg, see Figure 2). As Q2, Q3,
and Q5 harbour fewer than 2% of the variants, this proportion
substantially decreases when we make the additional restriction that
variants are detected as overlap variants. Consequently, approximately
half of the simulations result in either an empty set of overlap variants
in the covariate category, so that the covariate is excluded from the
final overlap model, or a negative effect estimate that is not
significantly different from 0; this behaviour is illustrated in the
QQ-plots. The inflation factors for Q1 and Q6 are 0.83 and 0.93, while
inflation factors calculated from the positive standardised statistics for
Q2, Q3, and Q5 are 1.46, 0.62, and 1.05. In summary, one-sided tests
for positive enrichment are well-calibrated for all covariates. There is
inflation for Q2 and deflation for Q3, which, respectively, contain
0.39% and 0.54% of the variants, suggesting that the type I error rate
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is not controlled very well when fewer than 1% of the variants are
positive for the covariate. In addition, two-sided tests for enrichment
in either direction may be tested for in the larger categories,
Q1 and Q6.
For assessment of power, we considered each of Q5 (1.4% of
variants) and Q1 (51.5% of variants) as being enriched for overlap, so
that any impact of the category proportions may also be assessed.
Covariate categories that are not designed as enriched for overlap each
give additional type I error results and can be averaged over the
simulation settings for each covariate (Supplementary Table S1);
individual results for all coefficients are given in Supplementary
Tables S2 and S3. The average error rates shown in Supplementary
Table S1 appear to have more stability than the individual rates.
For power assessment, the proportion of overlap causal variants that
fall within Q5 was assigned values from 5 to 50% (Figure 3;
Supplementary Table S4). For (N1, N2) set at (5000, 10 000) or
(10 000, 20 000), the detection power is close to 100% at 20%
enrichment, and is high at 10% enrichment; high power near 80%
is attained for (3000, 5000) when there is at least 10% enrichment.
The enrichment setting of p′12= 7× 10− 6 corresponds to the null
hypothesis of no enrichment (see Supplementary Information for
details), and the respective type I error estimates are 0.045, 0.039, and
0.035 for increasing study sizes. Results for Q1 in the case–control
setting and all quantitative trait results are shown in the
Supplementary Information.
Application to glycaemic traits
Results of the positive enrichment tests from COMET applied to
fasting glucose (FG), fasting insulin (FI) and 2-h glucose (2G) are
given in Table 3. Among potentially deleterious SNPS (0.67% of
pruned common variants), enrichment of overlap variants is detected
for FG-2G (two variants) and for FI-2G (one variant); see Table 3.
In addition, SNPs in mature miRNAs that have a regulatory effect
(ie, that are transcribed, though not translated) tend to be enriched for
variants associated with each of the three glycaemic traits. Nonetheless,
there are not more shared variants than expected by chance,
considering these marginal enrichments; Our results also indicate that
there is positive enrichment of variants associated with FG and with
FG-2G among SNPs that overlap potentially regulatory or regulatory
regions. Consequently, we tested tissue-specific regulatory annotations
for positive enrichment in an additional analysis.
Tissue-specific analysis of glycaemic traits
Results for tissue-specific analyses are shown in Table 4. Enrichment
in adipose tissue is not detected, as it only contains 0.12% of the
variants. Regulatory variants in pancreas tissues (and only pancreatic
islets) are enriched for marginal associations with FG, FI, and 2G, as
well as FG-2G shared variants, though they do not contain more
FG-FI variants than would be expected by chance (Table 4). Analysis
without accounting for the marginal distributions can be obtained by
excluding the offset term, resulting in a reduction of the P-value to
0.044 (pancreas tissues), suggesting enrichment. This illustrates that
marginal predictive factors are not necessarily predictive of overlap
variants, with the offset term able to account for any perceived overlap
that may in fact be due to chance. FI and FG associated variants are
enriched in liver tissue regulatory variants, though 2G variants are not.
COMET also detected that regulatory variants in cardiac muscle are
enriched for FG and those in cardiac and skeletal muscle are each
enriched for the FG-2G overlap.
Considering the five metabolic tissues collectively, there is enrich-
ment of each individual trait, as well FG-2G, though these signalsTa
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disappear when all available tissues are considered collectively. There is
an absence of FI-FG enrichment signals in tissue-specific analyses and
the collective tissue analysis suggests enrichment, but such overlap
variants are regulatory in a range of tissues that may be contributing to
the signal. The FI-FG SNPs (GRCh37/hg19 assembly) that are
regulatory in at least one metabolism-involved tissue are listed in
Supplementary Table S8, together with their nearest gene and
associated phenotypes. In Supplementary Table S9, analogous infor-
mation is given for the FI-FG overlap SNPs that are only regulatory in
a tissue that is not involved in metabolism, such as tissues from
cancerous liver, blood (cancerous and normal), cerebellum, skin, and
bone marrow.
DISCUSSION
We have proposed COMET as a computationally efficient method that
makes use of GWAS summary statistics to test categories for
enrichment of variants that are associated with multiple traits,
accounting for chance overlap due to the marginal associations of
each trait; individual trait-specific tests of enrichment are also
encompassed. In the association classification of variants we used a
Bayesian threshold of log10(ABF)40.695 (based on R= 20, π0= 0.99)
that corresponds to a P-value threshold of 0.004–0.01, depending on
the study size.8 This lenient threshold allows us to highlight new
overlapping variants not already known to be genome-wide significant,
and such variants that fall within an identified enrichment category
(ie, a category predictive of overlapping association) may have a
Figure 2 QQ-plots for the covariates in the most appropriate overlap model fit to simulated equal-sized case–control data (N1=3000 each and N2=5000
each). The model is fit to simulated data having p1=0.04, p2=0.02, p12=5×10−4 and no covariate categories are set-up as enriched.
Figure 3 COMET power for detecting Q5 as a category positively enriched
with overlap signals at coefficient significance level 0.05. In each of the
1000 simulations, the Q5 category (1.4% of common CEU SNPs LD-pruned
at r240.1) was set to have a certain proportion of shared causal variants. The
selected proportion of causal variants in this category p′12 is indicated in each
column, followed by the proportion among the causal variants p′12/p12, as a
percentage. Studies 1 and 2 are each equal-sized case–control studies of N1
each and N2 each, respectively. Type I error is denoted by bold font.
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stronger prior probability for having true associations with each trait.
Enrichment categories may also indicate a direction of refinement for
future searches for overlap variants. For example, our analysis suggests
that being a potentially deleterious variant is a predictive factor for
shared associated variants between glycaemic traits. Therefore, further
shared associations may be revealed through the analysis of whole-
exome or whole-genome data, which are enriched for potentially
deleterious variants that are generally poorly represented in other
genome-wide association arrays.
As a means of pre-assessing the usefulness of a set of functional
annotation covariates for our model, we compared the proportion of
covariate-positive trait-associated variants (with Po5× 10− 6) for an
assortment of traits. However, by considering the proportion of
associated variants that are positive for each covariate there is a range
of confidence interval sizes for the traits, as the confidence interval
depends on the number of associated variants that are listed in the
NHGRI-EBI GWAS catalogue.15 A further limitation is that the results
in the GWAS catalogue rely on a variety of studies, having a range of
sample sizes, which in turn influences the ability to detect trait
associations within each study. Therefore, the ability to detect
enrichment based on these proportions is heavily influenced by the
number of listed trait-associated variants. This pre-assessment gives
further support for our approach of detecting enrichment of
associated variants within covariates, rather than detecting enrichment
of covariates within associated variants.
In an application to glycaemic traits we detect enrichment of
associated variants (marginal and/or shared) within several functional
annotation classes, and identify well-established positive controls,
together with their biological support. The two glucose traits appear
to have more overlapping variants falling within some categories than
expected by chance, suggesting that these two traits are similar to each
other, as expected.
The missense variant rs1260326 (hg19 chr2:g.27730940T4C; in
GCKR) is associated with all three traits, and genome-wide significant
for FG,16 2G,17 blood metabolite levels, cardiovascular disease risk
factors, metabolic and lipid traits, gout, liver enzyme levels,
and chronic kidney disease.15 Additional variants within GCKR are
genome-wide significant for FI-related traits16 and Crohn’s
disease. An additional missense variant rs13266634 (hg19 chr8:
g.117172544C4T; in SLC30A8) is associated with both FG and 2G,
and genome-wide significant for T2D,18 FG,16 fasting proinsulin
levels,19 and glycated haemoglobin levels.20 These results are positive
controls, since the variants were known to be genome-wide significant
for the traits and our method both detects this overlap and suggests
that these numbers are greater than expected by chance.
The gene TCF7L2 is known to be associated with T2D and
glycaemic traits13 and within it we identify two overlap SNPs that
are in low LD (r2= 0.089) with each other: rs7903146 is detected for
each pair of traits and rs7079711 is identified for FI-FG. The SNP
rs7903146 acts as a positive control, since it is the lead SNP in TCF7L2
for associations with T2D,18 FI-related traits (interaction with BMI),5
Table 3 Results of the marginal and pair-wise inter-rater models overlap models fit to fasting glucose, fasting insulin and 2-h glucose
Covariates
Trait models Quantity
Q1: tran-
scribed, not
translated
Q2: translated, no
amino acid change
Q3: potentially
deleterious
Q5: potentially reg-
ulatory or regulatory
Q6: inter-
genic
Intercept: related to baseline association prob-
ability for marginal and shared beyond chance
Fasting insulin (FI) P-value
Estimate
STD error
Count
0.0326
0.141
0.0766
766
0.844
−0.466
0.450
5
0.189
0.258
0.293
12
0.113
0.0833
0.0687
271
0.194
0.0673
0.0778
836
o2×10−16
4.35
0.0873
Fasting glucose (FG) P-value
Estimate
STD error
Count
2.39×10−4
0.246
0.0704
920
0.974
−1.13
0.5790
3
0.491
0.00719
0.305
11
0.0494
0.105
0.0633
322
0.064
0.108
0.0709
960
o2×10−16
−4.27
0.0804
2-h glucose (2G) P-value
Estimate
STD error
Count
0.0416
0.190
0.110
353
0.624
−0.183
0.580
3
0.741
−0.376
0.580
3
0.356
0.0375
0.102
122
0.0675
0.168
0.112
399
o2×10−16
−5.20
0.127
(FG, FI) P-value
Estimate
STD error
Count
0.308
0.183
0.364
29
1
0
NA
0
0.216
0.799
1.01
1
0.623
−0.112
0.357
10
0.167
0.361
0.374
32
0.339
0.414
0.433
(FG, 2G) P-value
Estimate
STD error
Count
0.544
−0.0637
0.578
15
1
0
NA
0
3.98×10−5
2.94
0.745
2
0.0337
0.928
0.437
9
0.832
−0.517
0.537
11
0.302
0.661
0.640
(FI, 2G) P-value
Estimate
STD error
Count
0.305
0.327
0.639
9
1
0
NA
0
0.0102
2.43
1.046
1
0.783
−0.598
0.763
2
0.265
0.415
0.659
10
0.946
0.0516
0.763
Tests of positive enrichment are performed for all covariates and bold font indicates significance at level 0.05. Cell values of (1, 0, NA) indicate that the covariate was excluded from the final
overlap model. Two-sided P-values are given for intercept estimates.
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and FG-related traits (interaction with BMI)5 and is also genome-wide
significant for 2G16 and FG;16 this SNP is also our top signal for the
FI-2G overlap and for each of FG and 2G.
A further positive control is detection of the FG-2G variant
rs11708067 (in ADCY5), which is known to be associated with FG16
and is in LD with a known 2G-associated SNP rs2877716
(r2= 0.807).17 Each FI-2G variant that is regulatory in a
metabolism-involved tissue is within a gene containing FI- or T2D-
associated variants (Po5× 10− 6).
The top FI-FG signal is rs6984305 (in RP11-115J16.1), which is
regulatory in tissues from the pancreas, liver, cardiac muscle and
skeletal muscle. In the MAGIC data under analysis, this SNP is
genome-wide significant for FG (P-value 2.67× 10− 8; ABF 5.63) and
highly significant for FI (P-value 3.36× 10− 7; ABF 4.10); rs6984305 is
also in LD (r2= 0.614) with a known genome-wide significant FG
(interaction with BMI)-associated SNP, rs4841132.5
Several SNPs are of interest for further investigation, as they (and
SNPs in LD with them) have not been previously identified as
associated with glycaemic traits. The SNP rs4736324 (in LYPD2,
which harbours variants associated with body fat distribution) is
regulated in pancreas tissue/islets and is a FG-FI variant. Likewise,
rs2014712 (in KCNK9 and regulated in liver tissue) is an FG-FI variant
and variants in KCNK9 are associated with adiponectin levels,
cholesterol and CAD. Variant rs598725 (downstream RP4-60717.1)
is a FG-2G variant and is regulatory in both skeletal and cardiac
muscles. Most of the overlap SNPs that are regulatory in a non-
metabolic-involved tissue are not in LD with a variant that is
associated (at R= 20, π0= 0.99) with more than one glycaemic trait.
The exception is rs17036328 (within PPARG), which is in perfect LD
with several variants that meet significance for each of FG, FI
(genome-wide level) and 2G; two of these perfect LD variants are
regulatory in cardiac and skeletal muscles.
Enrichment of variants associated with FG, FI, 2G, and FG-2G
among regulatory variants in pancreatic islets concurs with the result
that islets are enriched in loci that are associated with FG and T2D.13
Among regulatory variants in liver tissue, there is enrichment of FI
and FG variants, though not 2G variants, aligning with the finding that
individuals with impaired FG have hepatic insulin resistance, while
those with impaired glucose tolerance (as measured by 2G) have
normal to slightly reduced hepatic insulin sensitivity.21 This suggests
that the liver plays a relatively more important role in influencing FG
than 2G. Enrichment of FI-associated variants in liver tissue may
coincide with insulin regulating glucose production in the liver during
the fasting state. Enrichment of glucose trait variants in cardiac and
skeletal muscle is likely linked with muscle being a target organ for
insulin.
A possible limitation of the proposed approach is that the SNPs
included in the analysis need to appear in both trait data sets, though
imputed results are often available, so this may not have a significant
impact. It is possible that, as we are limited by the set of SNPs available
in both studies, the associated SNP may be a tag SNP for the causal
variant, which is in a different covariate category, so that the
enrichment category does not contain this causal variant. However,
for covariate categories with a proportion of SNPs41%, there would
need to be some number of associated variants within the category in
order for enrichment to be detected. It is highly unlikely that the
majority of associated SNPs in the detected enrichment category are
each a tag SNP for a causal variant in a different category. Therefore,
even if this is true for an associated SNP, there is no change to the
general biological interpretation of the covariate category beingTa
bl
e
4
P-
va
lu
es
fo
rt
he
po
si
tiv
e
en
ric
hm
en
to
fg
ly
ca
em
ic
tr
ai
t-
as
so
ci
at
ed
va
ria
nt
s
(a
tB
ay
es
ia
n
de
ci
si
on
cr
ite
ria
R
=
2
0
,π
0
=
0
.9
9
)
in
si
x
di
ff
er
en
tt
is
su
es
,a
s
w
el
la
s
al
lt
is
su
es
av
ai
la
bl
e
in
R
eg
ul
om
eD
B
Tr
ai
t/t
is
su
e
Pa
nc
re
as
(p
an
cr
ea
tic
is
le
ts
on
ly
)
Li
ve
r
Ca
rd
ia
c
m
us
cl
e
Sk
el
et
al
m
us
cl
e
Ad
ip
os
e
Li
ve
r
ca
nc
er
Al
l(
5)
tis
su
es
in
vo
lv
ed
in
m
et
ab
ol
is
m
(p
an
is
le
ts
,
ra
th
er
th
an
pa
nc
re
as
Al
lt
is
su
es
Fa
st
in
g
in
su
lin
(F
I)
0.
00
7
79
(0
.0
0
4
7
2
)
0.
0
1
5
8
0.
2
9
4
0.
1
8
3
0.
6
8
7
0.
3
9
0
0
.0
0
1
8
9
(0
.0
0
2
7
4)
0.
4
0
1
Fa
st
in
g
gl
uc
os
e
(F
G
)
0.
00
5
90
(0
.0
1
1
6
)
0.
0
2
0
0
0.
0
0
6
6
4
0.
1
3
9
0.
7
3
9
0.
0
4
5
3
0
.0
0
77
6
(0
.0
0
6
7
0)
0.
0
5
8
4
2
-h
gl
uc
os
e
(2
G
)
0.
00
05
5
6
(0
.0
0
2
1
0
)
0.
1
4
0
0.
9
1
0
0.
0
7
1
0.
3
8
9
0.
6
0
4
0
.0
42
0
(0
.0
4
8
8
)
0.
0
9
0
0
FI
an
d
FG
0
.2
6
3
(0
.1
5
3
)
0.
7
3
3
0.
2
3
7
0.
5
8
7
1.
0
0
0
0.
3
9
3
0
.2
2
3
(0
.4
1
6
)
0.
0
31
7
FI
an
d
2
G
0
.4
9
2
(0
.4
1
8
)
0.
6
9
1
0.
5
0
6
1.
0
0
0
1.
0
0
0
0.
6
4
3
0
.4
3
3
(0
.5
5
2
)
0.
6
8
0
FG
an
d
2
G
0.
03
27
(0
.0
1
1
2
)
0.
3
1
5
0.
0
3
6
6
0.
0
48
0
1.
0
0
0
0.
5
8
2
0
.0
0
4
2
9
(0
.0
1
2
9
)
0.
3
4
4
P
an
cr
ea
s
tis
su
e
in
cl
ud
es
tis
su
es
fr
om
bo
th
pa
nc
re
at
ic
du
ct
s
an
d
pa
nc
re
at
ic
is
le
ts
.
B
ol
d
va
lu
es
in
di
ca
te
si
gn
ifi
ca
nc
e
at
le
ve
l
0
.0
5.
Multi-trait enrichment testing of shared variants
JL Asimit et al
348
European Journal of Human Genetics
enriched for associated SNPs, as a set of associated SNPs has been
detected in the category.
Alternative covariates to functional annotations may be trait × SNP-
specific, to inform about whether overlap SNPs occur more likely than
by chance within a certain trait feature, such as previously identified
trait-associated SNPs (using information obtained from NHGRI-EBI).
Additional covariate possibilities include SNP presence/absence in at
least one gene (+/− 50 kb buffer region) that has been identified as
harbouring a trait-associated variant (Po5× 10− 8), or a less stringent
classification (5× 10− 4oPo5× 10− 8), to increase the chances of
finding novel results.
The proposed approach may also be used for pathway-based
analyses, where the covariate indicates whether or not the SNP is in
a certain pathway, of relevance to one of the traits. For genes in a given
pathway (or group of related pathways), a covariate may be defined
according to presence/absence of the variant within at least one gene
(+/− 500 kb buffer) in the pathway; an additional covariate may be
defined as presence/absence of variant 500 kb away from gene and
closer than 1000 kb. This pair of covariates may be used in a separate
overlap model for each pathway (or pathway group) of interest.
In conclusion, our proposed procedure for identifying features
predictive of overlap informs biological interpretation and enables
refinement of the set of variants considered in further searches for
predisposing variants for both traits.
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